A comprehensive view of FDA Drug / Device Reviews. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Eisai and Biogen disappointed by EMA's negative opinion on lecanemab for early Alzheimer's; the humanized anti-amyloid-beta monoclonal antibody was under review for mild cognitive impairment
Published: July 26, 2024 by Biogen Inc.
FDA Advisory Committee reviewed AstraZeneca’s Imfinzi for resectable lung cancer; AEGEAN Phase III trial shows 32% risk reduction in recurrence, progression, or death vs. chemotherapy alone
Published: July 25, 2024 by AstraZeneca AB
AskBio secures FDA Fast Track and UK MHRA Innovation Passport for AB-1005 gene therapy; AB-1005 targets moderate Parkinson’s disease with ongoing Phase II REGENERATE-PD trial expansion in the U.S. and EU
Published: July 11, 2024 by Bayer AG
FDA approves Lilly's Kisunla™ for early symptomatic Alzheimer's; pivotal Phase 3 study showed up to 35% cognitive decline reduction over 18 months, 39% lower risk of disease progression
Published: July 02, 2024 by Eli Lilly & Co.
Lupin receives tentative U.S. FDA approval for Olopatadine Hydrochloride Ophthalmic Solution, 0.7%; product is a generic equivalent of Pataday® Once Daily Relief, expected annual U.S. sales USD 22 million
Published: June 27, 2024 by Contify Life Science News

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count